Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Abstract

Nicotine dependence is maintained by the aversive, depression-like effects of nicotine withdrawal and the rewarding effects of acute nicotine. GABA(B) receptor antagonists exhibit antidepressant-like effects in rodents, whereas GABA(B) receptor agonists attenuate the rewarding effects of nicotine. Recent studies with GABA(B) receptor positive modulators showed that these compounds represent potentially improved medications for the treatment of nicotine dependence because of fewer side-effects than GABA(B) receptor agonists. Thus, GABA(B) receptor agonists and antagonists, and GABA(B) receptor positive modulators may have efficacy as smoking cessation aids by targeting different aspects of nicotine dependence and withdrawal. The present study assessed the effects of the GABA(B) receptor agonist CGP44532, the GABA(B) receptor antagonist CGP56433A, and the GABA(B) receptor positive modulator BHF177 on the anhedonic aspects of nicotine withdrawal. Rats were prepared with stimulating electrodes in the posterior lateral hypothalamus. After establishing stable intracranial self-stimulation (ICSS) thresholds, rats were prepared with subcutaneous osmotic minipumps delivering either nicotine or saline for 7 or 14days. ICSS thresholds were assessed 6h post-pump removal. Thirty hours after pump removal, CGP44532, CGP56433A, and BHF177 were administered 30min prior to ICSS testing. Both GABA(B) receptor activation (CGP44532 and BHF177) and blockade (CGP56433A) elevated ICSS thresholds in all groups, resulting in exacerbated effects of nicotine withdrawal in the nicotine-treated groups. These similar effects of GABA(B) receptor activation and blockade on the anhedonic depression-like aspects of nicotine withdrawal were surprising and perhaps reflect differential efficacy of these compounds at presynaptic hetero- and autoreceptors, as well as postsynaptic, GABA(B) receptors.

• Authors: Styliani Vlachou, Neil E Paterson, Sebastien Guery, Klemens Kaupmann, Wolfgang Froestl, Deboshri Banerjee, M G Finn, Athina Markou
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 655 Issue 1-3 Pg. 52-8 (Mar 25 2011) ISSN: 1879-0712 [Electronic] Netherlands
• PMID: 21262222 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier B.V. All rights reserved.

Chemical References

• 3-amino-2-(S)-hydroxypropyl-methyl-phosphinic acid
• Benzoates
• GABA-B Receptor Agonists
• GABA-B Receptor Antagonists
• Phosphinic Acids
• Pyrimidines
• Receptors, GABA-B
• (3-(1-((3-(cyclohexylmethyl)hydroxyphosphinyl)-2-hydroxypropyl)amino)ethyl)benzoic acid
• gamma-Aminobutyric Acid
• Nicotine
• pyrimidine

Topics

• Animals
• Benzoates (pharmacology)
• Depression (chemically induced, metabolism)
• Drug Synergism
• GABA-B Receptor Agonists (pharmacology)
• GABA-B Receptor Antagonists (pharmacology)
• Male
• Nicotine (administration & dosage, adverse effects)
• Phosphinic Acids (pharmacology)
• Pyrimidines (chemistry, pharmacology)
• Rats
• Rats, Wistar
• Receptors, GABA-B (metabolism)
• Reward
• Self Stimulation (drug effects)
• Substance Withdrawal Syndrome (etiology, metabolism)
• gamma-Aminobutyric Acid (analogs & derivatives, pharmacology)